{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-268075","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.369005+00:00","generated_at":"2026-05-16T23:53:12.278078+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Climb Bio Q3 2025 cash $175.8M; pipeline advances with budoprutug and CLYM116 trials","bullets":["Cash and equivalents $175.8M as of Sep 30, 2025; runway expected through 2027.","R&D expenses $9.1M (Q3 2025) vs $6.2M (Q3 2024); G&A $5.8M vs $5.5M.","Phase 2 PrisMN trial of budoprutug initiated; dosing expected in coming weeks.","CLYM116 Phase 1 trial cleared; first subject dosing expected by year-end 2025.","New leadership: CFO Susan Altschuller, SVP Tech Ops Adam Villa, SVP People Ashley Jones."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-268075","json":"https://secwatch.observer/filing/0001193125-25-268075.json","markdown":"https://secwatch.observer/filing/0001193125-25-268075.md","text":"https://secwatch.observer/filing/0001193125-25-268075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312525268075/0001193125-25-268075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312525268075/clym-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:53:12.278078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}